Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors
DC Metz, RT Jensen - Gastroenterology, 2008 - Elsevier
Pancreatic endocrine tumors (PETs) have long fascinated clinicians and investigators
despite their relative rarity. Their clinical presentation varies depending on whether the …
despite their relative rarity. Their clinical presentation varies depending on whether the …
The diagnosis and medical management of advanced neuroendocrine tumors
GA Kaltsas, GM Besser, AB Grossman - Endocrine reviews, 2004 - academic.oup.com
Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that
originate from endocrine glands such as the pituitary, the parathyroids, and the …
originate from endocrine glands such as the pituitary, the parathyroids, and the …
The management of insulinoma
ON Tucker, PL Crotty, KC Conlon - Journal of British Surgery, 2006 - academic.oup.com
Background Insulinomas are rare tumours. Their clinical presentation, localization
techniques and operative management were reviewed. Methods An electronic search of the …
techniques and operative management were reviewed. Methods An electronic search of the …
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma
M Höpfner, AP Sutter, A Huether, D Schuppan… - Journal of …, 2004 - Elsevier
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancer-
related causes of death worldwide. Due to very poor 5-year-survival new therapeutic …
related causes of death worldwide. Due to very poor 5-year-survival new therapeutic …
[HTML][HTML] PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms
F Briest, P Grabowski - Theranostics, 2014 - ncbi.nlm.nih.gov
Gastroenteropancreatic neuroendocrine neoplasms are heterogeneous in their clinical
behavior and require therapies specially tailored according to staging, grading, origin and …
behavior and require therapies specially tailored according to staging, grading, origin and …
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies
This review describes the recent advances in the molecular events involved in pancreatic
cancer initiation, progression, and metastasis. Additionally, the importance of deregulated …
cancer initiation, progression, and metastasis. Additionally, the importance of deregulated …
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells
M Höpfner, A Huether, AP Sutter, V Baradari… - Biochemical …, 2006 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death
worldwide. Due to very poor 5-year-survival new therapeutic approaches are mandatory …
worldwide. Due to very poor 5-year-survival new therapeutic approaches are mandatory …
Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost …
A Lamarca, E Elliott, J Barriuso, A Backen… - Cancer Treatment …, 2016 - Elsevier
Background Chemotherapy is well-established in the treatment of patients with well-
differentiated neuroendocrine tumours (NETs) arising from the pancreas (pNETs); however …
differentiated neuroendocrine tumours (NETs) arising from the pancreas (pNETs); however …
Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas
B Papouchado, LA Erickson, AL Rohlinger… - Modern …, 2005 - nature.com
The epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of
many tumors. To analyze the expression of EGFR and activated EGFR in well-differentiated …
many tumors. To analyze the expression of EGFR and activated EGFR in well-differentiated …
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours
M Hopfner, V Baradari, A Huether… - Endocrine-Related …, 2006 - erc.bioscientifica.com
Gastrointestinal neuroendocrine tumours (NET) represent a heterogeneous tumour entity.
The anti-neoplastic therapy of advanced NET disease is still unsatisfactory and innovative …
The anti-neoplastic therapy of advanced NET disease is still unsatisfactory and innovative …